MEP13108A - Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b - Google Patents

Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b

Info

Publication number
MEP13108A
MEP13108A MEP-131/08A MEP13108A MEP13108A ME P13108 A MEP13108 A ME P13108A ME P13108 A MEP13108 A ME P13108A ME P13108 A MEP13108 A ME P13108A
Authority
ME
Montenegro
Prior art keywords
domain
antibody
cdr1
cdr2
seq
Prior art date
Application number
MEP-131/08A
Other languages
Bosnian (bs)
English (en)
Croatian (hr)
Inventor
Laura Borsi
Barbara Carnemolla
Enrica Balza
Patrizia Castellani
Luciano Zardi
Matthias Friebe
Christoph-Stephan Hilger
Original Assignee
Bayer Schering Pharma Ag
Philogen Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag, Philogen Spa filed Critical Bayer Schering Pharma Ag
Publication of MEP13108A publication Critical patent/MEP13108A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MEP-131/08A 2003-09-10 2004-09-01 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b MEP13108A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50188103P 2003-09-10 2003-09-10
EP03255633A EP1514561A1 (en) 2003-09-10 2003-09-10 Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
PCT/EP2004/009733 WO2005023318A1 (en) 2003-09-10 2004-09-01 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b

Publications (1)

Publication Number Publication Date
MEP13108A true MEP13108A (en) 2011-05-10

Family

ID=34130349

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-131/08A MEP13108A (en) 2003-09-10 2004-09-01 Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b

Country Status (28)

Country Link
US (2) US20050074401A1 (xx)
EP (3) EP1514561A1 (xx)
JP (1) JP2007505065A (xx)
KR (1) KR101129161B1 (xx)
CN (1) CN100482285C (xx)
AT (1) ATE499949T1 (xx)
AU (2) AU2004269897B2 (xx)
BR (1) BRPI0414272A (xx)
CA (1) CA2536256C (xx)
CR (2) CR8331A (xx)
DE (1) DE602004031635D1 (xx)
DK (1) DK1663320T3 (xx)
EA (1) EA010653B1 (xx)
EC (1) ECSP066499A (xx)
ES (1) ES2361743T3 (xx)
HK (1) HK1092375A1 (xx)
IL (1) IL173560A0 (xx)
ME (1) MEP13108A (xx)
NO (1) NO20061619L (xx)
NZ (1) NZ545640A (xx)
PL (1) PL1663320T3 (xx)
PT (1) PT1663320E (xx)
RS (1) RS20060176A (xx)
SG (1) SG162760A1 (xx)
SI (1) SI1663320T1 (xx)
UA (1) UA89759C2 (xx)
WO (1) WO2005023318A1 (xx)
ZA (1) ZA200602014B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
ES2337566T3 (es) * 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
ATE548052T1 (de) * 2008-01-17 2012-03-15 Philogen Spa Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
HUE034763T2 (en) * 2008-04-30 2018-02-28 Immunogen Inc Crosslinkers and their use
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
EP3029065B1 (en) * 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ed-b domain of fibronectin and uses thereof
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US10517238B2 (en) 2017-09-18 2019-12-31 Deere & Company Implement optimization by automated adjustments
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
JP7352040B2 (ja) * 2020-05-22 2023-09-27 フィロジェン エッセ．ピー．アー． 脳腫瘍の治療のためのＴＮＦα免疫コンジュゲート療法
CN111808161A (zh) * 2020-06-01 2020-10-23 北京大学 一种对生物化合物进行放射性标记的方法
AU2023206004A1 (en) 2022-01-04 2024-08-22 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE60121733T2 (de) 2000-02-24 2007-08-09 Philogen S.P.A. Zusamensetzungen und Verfahren zur Behandlung von Angiogenese in pathologischen Schädigungen
EP1259548A1 (en) * 2000-02-24 2002-11-27 Eidgenössische Technische Hochschule Zürich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
CA2468081A1 (en) * 2002-01-03 2003-07-10 Schering Aktiengesellschaft Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours
ES2337566T3 (es) * 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.

Also Published As

Publication number Publication date
CN1849144A (zh) 2006-10-18
IL173560A0 (en) 2006-07-05
CA2536256A1 (en) 2005-03-17
CA2536256C (en) 2013-02-26
CN100482285C (zh) 2009-04-29
DK1663320T3 (da) 2011-06-06
EP1663320A1 (en) 2006-06-07
WO2005023318A1 (en) 2005-03-17
ECSP066499A (es) 2006-10-10
AU2004269897B2 (en) 2009-11-05
PL1663320T3 (pl) 2011-07-29
ZA200602014B (en) 2007-05-30
US20090214423A1 (en) 2009-08-27
HK1092375A1 (en) 2007-02-09
EP2246070A2 (en) 2010-11-03
RS20060176A (xx) 2008-08-07
SI1663320T1 (sl) 2011-06-30
KR20060118430A (ko) 2006-11-23
NZ545640A (en) 2009-05-31
KR101129161B1 (ko) 2012-03-28
CR20110168A (es) 2011-06-03
ATE499949T1 (de) 2011-03-15
EP1663320B1 (en) 2011-03-02
ES2361743T3 (es) 2011-06-21
US20050074401A1 (en) 2005-04-07
EP1514561A1 (en) 2005-03-16
JP2007505065A (ja) 2007-03-08
CR8331A (es) 2006-10-04
AU2004269897A1 (en) 2005-03-17
EA200600494A1 (ru) 2006-08-25
AU2010200271A1 (en) 2010-02-18
EA010653B1 (ru) 2008-10-30
NO20061619L (no) 2006-04-10
DE602004031635D1 (de) 2011-04-14
BRPI0414272A (pt) 2006-11-07
UA89759C2 (ru) 2010-03-10
PT1663320E (pt) 2011-06-07
SG162760A1 (en) 2010-07-29

Similar Documents

Publication Publication Date Title
IL173560A0 (en) Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b
Tang et al. Imaging of HER2/neu-positive BT-474 human breast cancer xenografts in athymic mice using 111In-trastuzumab (Herceptin) Fab fragments
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
CN109963591A (zh) B7h3抗体-药物偶联物及其医药用途
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
HRP20160270T1 (hr) Monoklonska antitijela protiv glipikana-3
TNSN06087A1 (en) Therapeutic binding molecules
WO2006089133A8 (en) Anti-cd19 antibodies and uses in oncology
RS54088B1 (en) B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES
WO2006133450A3 (en) Anti-cd19 antibody therapy for the transplantation
RS54393B1 (en) HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
WO2006121852A3 (en) Anti-cd19 antibody therapy for autoimmune disease
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
PE20020871A1 (es) Moleculas de enlace terapeuticas
PL359854A1 (en) Antibodies to human mcp-1
AU2003219370B2 (en) Antibodies derived rom anti ED-B L19 and targeting tumor vasculature
DK1411962T3 (da) Terapi for pancreacancer med monoklonalt stof
Sharkey et al. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting
JP2007508352A5 (xx)
Pimm et al. Influence of a syngeneic anti-idiotypic antibody response to a mouse anti-tumour monoclonal antibody on biodistribution of its radiolabelled Fc-intact monovalent Fab/c fragment
UA84539C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с cd40, фармацевтическая композиция, которая его содержит, и применение антитела для производства лекарственного средства для лечения cd 40-отрицательной опухоли у человека
MXPA06002757A (en) Targeting of tumor vasculature using radiolabelled antibody l19 against fibronectin ed-b